Recruiting NCT07167537
A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: OL-CD19-GDT.
- Who it may be relevant to
- Registry conditions: Systemic Sclerosis (SSc), Primary Sjogren's Syndrome. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
An Open-Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Allogeneic CAR-T Cell Therapy (OL-CD19-GDT) in the Treatment of Relapsed/Refractory Autoimmune Diseases
Overview
This study aims to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of OL-CD19-GDT in relapsed/refractory autoimmune diseases.
Detailed description
This is an open-label, single-arm, clinical study to evaluate the efficacy and safety of CAR-T therapy OL-CD19-GDT in the treatment of Relapsed/ Refractory Autoimmune Diseases such as SSc and pSS.
Interventions
- Biological OL-CD19-GDT
OL-CD19-GDT will be given through IV bolus with ascending dose levels to determine the RDE and RP2D as specified in the protocol
Primary outcome measures
- Dose-limiting toxicity (DLT) [Time frame: After OL-CD19-GDT administration up to 30 days (Day 1-Day 30)]
- Treatment emergent adverse event (TEAE) incidence and severity [Time frame: From lymphodepletion through study completion, up to 2 years]
Secondary outcome measures (7)
- Overall Response Rate [Time frame: Baseline through study completion, up to 2 years]
- Cmax of OL-CD19-GDT [Time frame: Baseline through study completion, up to 2 years]
- Tmax of OL-CD19-GDT [Time frame: Baseline through study completion, up to 2 years]
- AUC 0-28 days [Time frame: Baseline through study completion, up to 2 years]
- Serum cytokines [Time frame: From lymphodepletion till day 90]
- Level of Immunogenicity [Time frame: Baseline through study completion, up to 2 years]
- Level of RCR [Time frame: Baseline through study completion, up to 2 years]
Eligibility criteria
Inclusion criteria
- Adults aged 18-65 years old
- ECOG 0-2
- Adequate organ function
- Females of childbearing potential (FCBP) must have a negative pregnancy test at screening and must agree to use a highly effective contraceptive method starting from the time of lymphodepletion and for 2 years after dosing of the IMP
- SSc specific:
a)Fulfilling the 2013 ACR/EULAR classification criteria of SSc; b) mRSS score >10; c) at least one vital organ involvement besides the skin; d)relapsed or refractory to at least one immunosuppressant or biologic.
- pSS specfic: a)Fulling the 2016 EULAR/ACR classification critieria for pSS; b) anti-Ro/anti-SSA antibody positive; c) ESSDAI score ≥5 ; d)relapsed or refractory to at least one immunosuppressant or biologic.
Exclusion criteria
- Active uncontrolled infection
- Serologic evidence of chronic hepatitis B virus (HBV) infection and unable or unwilling to receive standard prophylactic antiviral therapy or with detectable HBV viral load
- Serologic evidence of hepatitis C virus (HCV) infection without completion of curative treatment or with detectable HCV viral load
- HIV antibody positive
- Syphilis antibody positive
- Active tuberculosis, untreated or inadequately treated latent tuberculosis infection (LTBI)
- History of serious infection within 3 months prior to screening (defined as requiring hospitalization or intravenous antimicrobial therapy), or history of oral antimicrobial therapy within 1 month prior to screening (e.g., viral infections, opportunistic infections, including but not limited to severe cytomegalovirus or herpes virus infections)
- Congenital long QT syndrome or a corrected QTcF interval of ≥480 ms at screening (unless secondary to pacemaker or bundle branch block)
- Uncontrolled hypertension (blood pressure ≥160/100 mm Hg repeatedly), unstable angina, congestive heart failure (greater than New York Heart Association class II), electrocardiographic evidence of acute ischemia, coronary angioplasty or myocardial infarction within 6 months prior to screening, uncontrolled atrial or ventricular cardiac arrhythmia, poorly controlled diabetes or other endocrine diseases, severe chronic pulmonary disease, or other serious medical condition which is likely to significantly impair the patient's ability to tolerate the study treatment
- history of organ transplant
- Pregnancy or lactating women
- Use of any other experimental medication within 4 weeks or 5 half-lives prior to start of study drug
- Use of biologics within 10 weeks, stem cell transplant within 6 months prior to the start of study drug
- Prior CAR-T treatment
- Received live or attenuated vaccine within 4 weeks of Cycle 1 Day 1
- Presence of other autoimmune or auto-inflammatory diseases that may affect study assessments, such as rheumatoid arthritis, gout, or active fibromyalgia syndrome.
- Limited to patients diagnosed with SSc: at risk for scleroderma renal crisis; SSc-associated gastric antral vascular ectasia; Severe gastrointestinal involvement leading to malabsorption or intestinal failure
- Limited to patients diagnosed with pSS: primary biliary cholangitis
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Beijing GoBroad Hospital — Beijing
Identifiers
NCT: NCT07167537 · OL-CD19-GDT-002